Share your videos with the world

The less the chance to empty it, the greater the rate at which the bladder fills.

Time out! Did you know that more than 33 million adults in the United States1 – or one in six2 – deal with bladder control problems? Many women suffer in silence, frustrated with their current treatment but unaware that other options exist. This November, in observance of National Bladder Health Awareness Month, women around the country will take a Girls' Time Out to face the moments when they have struggled with bladder control problems. For more information, visit www.FacingOurMoments.com To view Multimedia News Release, go to http://www.multivu.com/players/English/46562-medtronic-bladder-health-awareness-month-campaign/

The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads. The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress. To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/

Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma. To view the multimedia release go to: http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/